Compared with brain organoids grown from ordinary human cells (top), those with a Neanderthal gene variant (bottom) differ in appearance and behavior.
Aside from dark matter and the dark energy that comprised the universe, there remained to be 5 percent of what was called the “ordinary matter.” About two-thirds of this ordinary matter was left unaccounted for until now. ( Harvard-Smithsonian Center for Astrophysics )
After a 20-year-long experiment, a team of international scientists detects the last of the missing intergalactic material predicted to be created by the Big Bang.
Specifically, the team was finally able to detect the missing parts of the “ordinary matter” that makes up everything in the universe, from the stars to the cores of black holes. This ordinary matter is different from the “dark matter” that comprised the bulk of the universe’s mass. The dark matter remained to be undetected until now.
It seems that Microsoft isn’t done experimenting with blockchain technology.
Microsoft and Ernst & Young (EY) announced the launch of a blockchain solution for content rights and royalties management on Wednesday.
The blockchain solution is first implemented for Microsoft’s game publisher partners. Indeed, gaming giant Ubisoft is already experimenting with the technology.
Infrared cameras are the heat-sensing eyes that help drones find their targets, even in the dead of night or through heavy fog.
Hiding from such detectors could become much easier, thanks to a new cloaking material that renders objects—and people—practically invisible.
“What we have shown is an ultrathin stealth ‘sheet.’ Right now, what people have is much heavier metal armor or thermal blankets,” says Hongrui Jiang, the Lynn H. Matthias Professor and Vilas Distinguished Achievement Professor of electrical and computer engineering at the University of Wisconsin-Madison.
The exponential potential of longevity technologies.
Jim Mellon became a billionaire by pouncing on a wide variety of opportunities, from the dawn of business privatization in Russia to uranium mining in Africa and real estate in Germany. But all of that might eventually look small, he says, compared to the money to be made in the next decade or so from biotechnologies that will increase human longevity well past 100.
The British investor is so enthusiastic about these technologies that he co-authored a 2017 book about them, Juvenescence: Investing in the Age of Longevity, and launched a company, Juvenescence Ltd., to capitalize on them. “Juvenescence” is a real word — it’s the state of being youthful. Says Mellon, who is 61: “I’m hoping that this stuff works on me as well as on my portfolio.”
Juvenescence Ltd., which has raised $62.5 million from Mellon and some partners, has invested in or is close to confirming investments in nine biotech companies. He won’t discuss most of them. But one of the deals was an 11 percent stake in Insilico Medicine, a company applying machine-learning techniques to drug discovery. Insilico Medicine and Mellon’s company also formed a joint venture called Juvenescence AI to investigate the therapeutic properties of specific compounds. Mellon is particularly optimistic that this venture can develop a “senolytic” drug that helps the body clear out cells that have stopped dividing and can damage other cells.
An interview with Dr. Vadim Gladyshev, Harvard University.
We have recently had occasion to have a chat with Dr. Vadim Gladyshev, Professor of Medicine and Director of Redox Medicine at Brigham and Women’s Hospital, Harvard Medical School, in Boston, Massachusetts. He is an expert in aging and redox biology and is known for his characterization of the human selenoproteome. His research laboratory focuses on comparative genomics, selenoproteins, redox biology, and, naturally, aging and lifespan control.
Dr. Gladyshev graduated from Moscow State University, in Moscow, Russia; his postdoctoral studies in the 1990s took place at the National Heart, Lung, and Blood Institute, and the National Cancer Institute, in Bethesda, Maryland. Even when he was young, he was very much interested in chemistry and experimental science: he twice won the regional Olympiad in chemistry and graduated from high school with a gold medal. He also graduated with the highest honors from Moscow State University. This enviable track record is even more impressive considering that Dr. Gladyshev completed music school and high school at the same time and became a chess player equivalent to national master during his college years.
You’ll have a chance to meet Dr. Gladyshev at our upcoming New York City conference, Ending Age-Related Diseases, on July 12; if you can’t attend, you can at least enjoy our interview with Dr. Gladyshev below.
At least in the developed world, cancer, heart diseases, and neurodegenerative diseases are among the greatest causes of mortality. One emerging and very promising way to prevent or cure these diseases is through bio-nanotechnology.
Nanotechnology is the design, synthesis and application of materials or devices that are on the nanometer scale (one billionth of a meter). Due to the small scale of these devices, they can have many beneficial applications, both in industry and medicine. The use of nanodevices in medicine is called nanomedicine. Here, we will look at some applications of nanomedicine in curing or preventing the diseases that are most likely to kill us.
Early adopters, speculators and Geeks are never sufficient to bring a new paradigm to market. Mass appeal and adoption of a mechanism that requires education and a change of behavior is never ‘fait accompli’—until it reaches a tipping point. Once at the tipping point, it can go viral without a structured PR campaign and with risks tied only to technology and scalability.